Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA - Timothy Fitzgerald; Maryia Zhdanava; Dominic Pilon; Aditi Shah; Patrick Lefebvre; Steven R. Feldman (Adis, Springer Healthcare, 2023)